Literature DB >> 19188015

Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes.

Sascha Keller1, Anne-Kathleen König, Frederik Marmé, Steffen Runz, Silke Wolterink, Dominique Koensgen, Alexander Mustea, Jalid Sehouli, Peter Altevogt.   

Abstract

Exosomes are membrane vesicles that are released from many different cell types. Tumor derived-exosomes play a role in immune suppression. We hypothesized that in ovarian carcinoma patients exosomes initially produced at the local abdominal site may become systemic. We examined paired samples of ascites and blood from ovarian carcinoma patients for the presence of exosomes. We also studied the requirements for exosomal uptake by immune cells, the role of phosphatidyl-serine (PS) as uptake signal and the effect of exosome application on tumor growth. We used exosomes from ovarian carcinoma cell lines, malignant ascites and sera from ovarian carcinoma patients isolated by ultracentrifugation. PS-displayed by exosomes was detected by Anexin-V-FITC staining of latex beads adsorbed exosomes. For uptake experiments, labeled exosomes were exposed to cells in the presence or absence of cold Annexin-V as competitor. Uptake was examined by fluorescent microscopy and cytofluorographic analysis. Effects of exosomes on tumor growth were studied using SKOV3ip ovarian carcinoma cells in CD1 nu/nu mice. We found that malignant ascites-derived exosomes cargo tumor progression related proteins such as L1CAM, CD24, ADAM10, and EMMPRIN. We observed that exosomes become systemic via the blood stream. Uptake of ovarian carcinoma exosomes by NK cells was found to require PS at the exosomal surface but the presence of PS was not sufficient. Application of malignant ascites-derived exosomes to tumor bearing mice resulted in augmented tumor growth. Exosomes from the serum of tumor patients could be isolated from only one ml of blood and this analysis could serve for diagnostic purposes. We propose that tumor-derived exosomes could play a role in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19188015     DOI: 10.1016/j.canlet.2008.12.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  126 in total

Review 1.  Microvesicles and viral infection.

Authors:  David G Meckes; Nancy Raab-Traub
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

Review 2.  Ectosomes as modulators of inflammation and immunity.

Authors:  S Sadallah; C Eken; J A Schifferli
Journal:  Clin Exp Immunol       Date:  2010-10-29       Impact factor: 4.330

Review 3.  Exosomes: immune properties and potential clinical implementations.

Authors:  Nathalie Chaput; Clotilde Théry
Journal:  Semin Immunopathol       Date:  2010-12-21       Impact factor: 9.623

Review 4.  The biological significance and clinical applications of exosomes in ovarian cancer.

Authors:  Kalpana Deepa Priya Dorayappan; John J Wallbillich; David E Cohn; Karuppaiyah Selvendiran
Journal:  Gynecol Oncol       Date:  2016-04-10       Impact factor: 5.482

Review 5.  Functional interplay between tetraspanins and proteases.

Authors:  María Yáñez-Mó; Maria Dolores Gutiérrez-López; Carlos Cabañas
Journal:  Cell Mol Life Sci       Date:  2011-06-18       Impact factor: 9.261

6.  Protein targeting to exosomes/microvesicles by plasma membrane anchors.

Authors:  Beiyi Shen; Ning Wu; Jr-Ming Yang; Stephen J Gould
Journal:  J Biol Chem       Date:  2011-02-07       Impact factor: 5.157

Review 7.  Exosomes and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment.

Authors:  C-Y Wu; S-L Du; J Zhang; A-L Liang; Y-J Liu
Journal:  Cancer Gene Ther       Date:  2016-12-16       Impact factor: 5.987

Review 8.  Exosome platform for diagnosis and monitoring of traumatic brain injury.

Authors:  Douglas D Taylor; Cicek Gercel-Taylor
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-09-26       Impact factor: 6.237

9.  Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments.

Authors:  Gautam N Shenoy; Maulasri Bhatta; Jenni L Loyall; Raymond J Kelleher; Joel M Bernstein; Richard B Bankert
Journal:  Immunol Invest       Date:  2020-04-17       Impact factor: 3.657

10.  Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.

Authors:  Susan K Lutgendorf; Premal H Thaker; Jesusa M Arevalo; Michael J Goodheart; George M Slavich; Anil K Sood; Steve W Cole
Journal:  Cancer       Date:  2017-11-07       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.